Trimethoprim-Sulfamethoxazole · Bactrim

What is Trimethoprim-Sulfamethoxazole?

Trimethoprim-sulfamethoxazole is a combination of two antibacterial agents that synergistically inhibit sequential steps in bacterial folic acid metabolism.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Bactrim, Trimethoprim / Sulfamethoxazole

Drug type

Small molecule

Targets

dihydrofolate reductase, dihydrofolate synthase

Mechanism

Inhibitor of dihydrofolate reductase and dihydrofolate synthase

Pathways

bacterial folic acid metabolism

Therapy area

Infectious disease

Developer

Sun Pharm Industries

In trials of

INVA

FDA status

Approved as Bactrim (July 30, 1973), NDA017377 · FDA label

✅ FDA-approved uses

• Urinary tract infections
• Acute otitis media
• Acute exacerbations of chronic bronchitis
• Shigellosis

From the indications section of the FDA label (version of Dec 30, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mycobacterium Abscessus InfectionMycobacterium Abscessus Pulmonary DiseaseNon-Tuberculous Mycobacteria Pulmonary DiseaseNon-Tuberculous Mycobacterial (NTM) Infections

Sources

• FDA label Bactrim (2024-12-30), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT07485010

Updated Oct 3, 2026.